Kudo M - Search Results

1

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.

Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. Kelley RK, et al. Among authors: kudo m. J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22. J Clin Oncol. 2021. PMID: 34292792 Free PMC article. Clinical Trial.

2

Imaging blood flow characteristics of hepatocellular carcinoma.

Kudo M. Kudo M. Oncology. 2002;62 Suppl 1:48-56. doi: 10.1159/000048276. Oncology. 2002. PMID: 11868785

3

Early detection and curative treatment of early-stage hepatocellular carcinoma.

Kudo M. Kudo M. Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S144-8. doi: 10.1016/s1542-3565(05)00712-3. Clin Gastroenterol Hepatol. 2005. PMID: 16234064 Review.

4

Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study.

Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, Takahashi S, Kitai S, Inoue T, Minami Y, Ueshima K. Kudo M, et al. Oncology. 2007;72 Suppl 1:132-8. doi: 10.1159/000111719. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087194

5

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:1-12. doi: 10.1159/000181865. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092266 Review.

6

Impact of interferon therapy after curative treatment of hepatocellular carcinoma.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:30-41. doi: 10.1159/000173422. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092270

7

PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.

Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Nagai T, Minami Y, Ueshima K. Takahashi S, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:91-8. doi: 10.1159/000173429. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092277

8

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.

Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Minami Y, Chung H. Ueshima K, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:106-13. doi: 10.1159/000173431. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092279

9

Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial.

Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T, Sato K, Yamamoto S, Hinotsu S, Sato T. Okusaka T, et al. Among authors: kudo m. J Hepatol. 2009 Dec;51(6):1030-6. doi: 10.1016/j.jhep.2009.09.004. Epub 2009 Oct 1. J Hepatol. 2009. PMID: 19864035 Clinical Trial.

10

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Kudo M. Kudo M. Int J Clin Oncol. 2010 Jun;15(3):242-55. doi: 10.1007/s10147-010-0089-y. Epub 2010 May 28. Int J Clin Oncol. 2010. PMID: 20509038 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,554 results

Search Page

Filters